Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

Published on February 14, 2022

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Continue reading on website
Other news

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

February 14, 2022
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

How to Grow Your Business by 500%

February 14, 2022
There may not be a "one size fits all" formula for success, but these proven-by-experience strategies will help you achieve dramatic and consistent growth.